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Abstract
Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus 
infecting humans worldwide. Up to date, there are no antiviral treatments or 
vaccines approved to treat or prevent CHIKV for which treatments remain symp-
tomatic based on clinical manifestations. Hence, designing effective therapies to 
either prevent or treat CHIKV infection is of paramount importance. Interestingly, 
monoclonal antibodies (mAbs) are known to be significantly important in mediat-
ing protective immunity in CHIV infection. During the last decades, numerous 
animal studies have reported the protective and prophylactic efficacy of human 
and mouse anti-CHIKV mAbs isolated from convalescent patients. However, the 
therapeutic benefits of these anti-CHIKV mAbs can be limited by multiple factors. 
Thus, it becomes pertinent to better understand the CHIKV infection dynamics, 
mitigate the undesired mAbs-associated effects and improve therapies. In this 
review, we critically discuss CHIKV antiviral infectious mechanisms and address 
how the improved understanding of the latter may pave the way to better targeted 
immunotherapies.
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1. Introduction
Chikungunya virus (CHIKV) is an arthropod-borne virus firstly discovered 
during the Tanzanian outbreak in 1952 and isolated a year later (1953) from patient 
serum and mosquitoes [1]. CHIKV is a worldwide epidemic threat responsible for 
self-limited fever, maculopapular rashes, and debilitating polyarthralgia in most 
(90–92%) infected patients [1, 2]. Its name, meaning “that which contorts or bends 
up” in “Kimakonde”, a Tanzanian and Mozambican vernacular language, stems 
from the stooped posture exhibited by infected patients [3–6]. In endemic areas, 
CHIKV can be misdiagnosed as it displays dengue (DENV) or zika virus (ZIKV) 
like symptoms [1, 7]. Although less lethal, CHIKV-associated mortality rate can be 
influenced by other factors, including immunocompromised individuals, new-
borns from high viremic mothers or patients with preexisting arthritis [1]. CHIKV 
represents a serious economic burden, affecting the physical status of infected 
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patients, restraining them from working for up to 35 days, as reported during the 
2007 Indian outbreak [8]. For that reason, CHIKV was categorized as a biodefense 
pathogen by the National Institute of Allergy and Infectious Diseases (NIAID) in 
the USA [9]. Presently, there are no clinically licensed vaccines or therapies to treat 
CHIKV. Nonetheless, several pre-clinical animal models using antibody-based 
immunotherapy have shown some promising results in preventing and treating 
CHIKV infections [1, 7, 9, 10]. Despite several obstacles that have to be overcome to 
reach clinical fruition of such therapy [11], mAbs therapies offer better therapeutic 
avenues with respect to emerging disease outbreaks [12]. Hence, this review suc-
cinctly describes CHIKV characteristics (Transmission, structure and diagnosis) 
and highlights the potential therapeutic usage of mAbs based on their protective 
role in naturally occurring humoral immunity following CHIV infection. Lastly, we 
briefly discuss some challenges associated with mAbs therapy and propose future 
alternative therapeutic approaches.
2. Chikungunya’s transmission cycle
CHIKV can be transmitted either horizontally from human to human through 
mosquito bites (Aedes species) [1] or vertically from a mother to a child during preg-
nancy or at birth, thus causing severe neonatal infection [1, 13, 14]. However, the rate 
of CHIKV transmission can be affected by the geographical location and the vector. 
It has been historically reported that CHIKV was predominant in Sub-Saharan Africa 
(SSA), Southeast Asia tropical and sub-tropical regions, where two different transmis-
sion cycles occur [15]. In rural areas, CHIKV replicates through a sylvatic transmission 
cycle (animal to human transmission via the mosquito), involving forest or savanna 
Aedes mosquitoes (A. furcifer and A. africanus) and animals (domestics and non-
domestics), representing the main CHIKV reservoirs within this cycle [16]. The urban 
transmission cycle is mediated by A. albopictus (also known as Asian tiger mosquito) 
and A. aegypti, both maintaining the human-to-human transmission, thus making 
humans the principal CHIKV reservoirs in the urban epidemic cycle (Figure 1). 
Interestingly, Chikungunya fever outbreaks in Asia have been associated with only the 
Figure 1. 
CHIKV transmission cycle: Two cycles known as sylvatic and urban characterized the CHIKV transmission 
cycle. While the sylvatic predominantly occurs in Africa and circulates between primates, rodents and other 
vertebrates, the urban counterparts is commonly observed in Asia, where CHIKV is horizontally transferred 
from human to human through mosquito bites or blood meal.
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urban CHIKV transmission cycle, while the African counterparts are related to both 
sylvatic and urban transmission cycles [15, 17]. Based on this evidence, it can hypo-
thetically be suggested that the CHIKV transmission cycle before 1952 was restricted to 
the sylvatic cycle and that its urban transmission resulted from demographic expan-
sion through deforestation or migration of CHIKV infected travelers from rural to the 
most populated urban cities. While the natural factors sustaining CHIKV infection 
remain elusive [16], it can be hypothesized that simultaneous presence of Aedes specie 
mosquitoes and CHIKV carriers (even with very low viral load in the blood) in a given 
area is enough for the resurgence of CHIKV-associated outbreaks.
3. Clinical manifestations of chikungunya fever
Chikungunya virus (CHIKV) is an emerging and re-emerging arbovirus associ-
ated with high morbidity, characterized by multiple clinical symptoms, with typical 
and/or atypical signs. CHIKV infection can be broken down into three phases, 
including the acute (the first 21st days following the onset of clinical symptoms), 
post-acute (from the 3rd week till the end of the 3rd month) and chronic phase 
(3 months following the onset of clinical symptoms) [1]. Therefore, chikungunya 
can present diverse clinical symptoms, for which 3–25% of infected individuals 
are asymptomatic (Figure 2) [18]. During the symptomatic phase, the majority of 
infected patients (90–95%) develop long lasting clinical symptoms coinciding with 
viremia peak (Elevated viral load ranging between 105 and 1012 viruses per milliliter 
of blood) and manifested as debilitating polyarthralgia, myalgia and arthralgia 
which are rarely fatal (1 in 1000) and not observed in dengue fever [18–20]. 
Atypical cases of CHIKV occur less frequently and mainly affect elderly, immuno-
compromised individuals and neonates from viremic mothers [1, 18]. The clinical 
manifestations associated with these atypical cases include severe neurological 
dysfunctions (Encephalitis), ocular changes, cardiovascular defect, preterm birth, 
hyperpigmentation, bullous dermatosis and Guillain-Barré syndrome [1, 18].  
Figure 2. 
Acute CHIKV clinical symptoms: During the symptomatic phase, CHIKV reportedly causes self-limited 
fever, as well as debilitating polyarthralgia in most (85–92%) infected patients [18–20]. Also, CHIKV can 
manifest atypical dermatological symptoms (42%) including edema, hemorrhagic bullous skin lesions, 
hyperpigmentation [21] and neurological symptoms, characterized by encephalopathy, encephalitis, Guillain–
Barre or encephalomyelora-diculitis [22].
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Yet, the mechanisms contributing to the long-lasting clinical symptoms remain 
elusive. An attempt to elucidate this mechanism was made by Reddy et al., 2017, 
demonstrating CHIKV’s ability to evade host immunity as a result of CHIKV E1 
glycoprotein homology to the host human counterpart [23]. Consequently, a more 
detailed understanding of CHIKV replication and infectious cycle is necessary to 
mitigate these undesired effects.
4. Chikungunya virus genome structure and infectious cycle
CHIKV is a small enveloped virus with a positive single-strand RNA virus 
belonging to the Alphavirus genus from the Togaviridae family [1, 21]. It is also 
referred to as an arbovirus (for arthropod-borne virus) due to arthropods trans-
mission (Aedes mosquitoes) [21]. CHIKV has an RNA genome of approximately 
11.8 kb, comprising two open reading frames (ORFs), known as 5’caped ORF (7424 
nucleotides) and 3’polyadenylated ORF (3732 nucleotides), linked by a junction 
region [22]. The 5’end is protected by a 7-methylguanosine (7MG) cap, with the 
ORF accounting for 66% of the genome encoding a precursor protein, which upon 
processing produces four nonstructural proteins (nsP1–4) responsible for CHIKV 
replication in host cell cytoplasm upon entry [1, 22]. On the other hand, the 3’ORF 
ends with a polyadenylation signal (3’poly-A tail) and encodes another precursor 
protein, generating five structural polyprotein comprising: the capsid C, envelop 
glycoproteins (E1, E2 and E3) and the 6 K protein [1, 22]. Figure 3A give a graphic 
representation of CHIKV genome. Once matured (after replicating in host cells), 
the virion particle has about 70 nm diameter and possesses 240 copies of capsid 
proteins embedded in 80 spikes of envelope trimers (glycoproteins E2/E1), which 
are inserted within the plasma membrane of the infected cells (to evade host immu-
nity) that they use to bud out of the host cells through a secretory pathway [1, 22] 
(Figure 3B). Therefore, elucidating CHIKV replication cycle in both mammalian 
and mosquito cells becomes pertinent to develop efficient therapies.
CHIKV primarily replicates in the epithelial cells of mosquito midgut before 
migrating into the salivary glands where they keep replicating throughout the 
insect life, prior dissemination into the bloodstream of mammalian host, following 
mosquito bite/blood meal [1, 25]. Once deposited in the human bloodstream or skin 
after an infected mosquito bite (or blood meal), CHIKV firstly replicates within 
fibroblasts and macrophages found at the site of inoculation [16]. Thereafter, CHIKV 
systemically propagates within the body through the lymphatic system to multiple 
replication sites, where prominent disease symptoms occur (lymph nodes, spleen, 
skin, muscles, peripheral joints, brain, liver and tendons) despite innate immunity 
[16]. Notably, CHIKV replication in peripheral tissues is associated with elevated 
viral loads (>109 virus particles/ml), which is conducive for mosquito transmission 
during episodic bloodmeal or bite [16, 26]. Moreover, CHIKV can be transmitted to 
humans in various ways, including infected needles, contaminated blood donation, 
organ graft and from viremic mother to newborn [1, 27]. In this regard, Campos et 
al., 2017 study primarily highlighted the presence of CHIKV in the breast milk of an 
infected mother, who tested positive for serum and urine [28]. Fortunately, this study 
did not reveal a breastfeeding transmission capacity of the infected breast milk, as 
the 3-month-old newborn CHIKV serology and reverse transcriptase-polymerase 
chain reaction (RT-PCR) tested negative [1, 28]. In light of the latter results, it is 
worth mentioning that only the structural proteins (surface glycoproteins E2 and E1) 
are present on the outer surface of CHIKV envelop and are endowed with antigenic 
potential, able to elicit activation of host immune defense mechanisms [10].
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5. CHIKV induced immune response
5.1 The role of innate immunity in chikungunya infection management
The innate immune system refers to the first non-physical and non-specific 
defense mechanisms to encounter invading pathogens or foreign elements immedi-
ately or hours following the appearance of their antigens within the body [29]. To 
perform its protective role, the host innate immunity relies on antigen- presenting 
cells (APC) such as macrophages (Mc) and dendritic cells (DC) to neutral-
ize foreign antigens and subsequently present it in a specific way to specialized 
lymphocytes B (antibody producing cells) and T-cells of the adaptive immunity 
in secondary lymphoid organs (spleen and ganglions) [30, 31]. Conventionally, 
all APCs are endowed with the ability to capture an antigen originating from 
extracellular or intracellular milieu and present it to CD4+ or CD8+ T cells, using 
major histocompatibility complex II (MHC-II) or I (MHC I) associated peptides 
respectively [30–32]. However, DCs are endowed with the unique potency to prime 
CD4+ and CD8+ T-cells (in secondary lymphoid organs) due to their ability to 
cross-present captured foreign antigens using MHC-II/I complexes [32–34]. Under 
normal conditions, DC cells exist in immature and inactivated states, hence acting 
as the sentinel of the immune system [31, 34, 35]. However, DCs are activated into 
a mature state once exposed to the antigenic determinant of the foreign organism. 
This DC protective role was illustrated by Long et al., 2013 reporting increased DCs 
presence at CHIKV infection site 24 and 36 h post infection [36]. Additionally, the 
latter report highlighted that mice harboring DCs deficiency for dendritic immuno-
genic receptor (DCIR) displayed more severe CHIKV related symptoms (increased 
inflammation, edema, weight loss and damage of inoculated foot and the ankle 
joint) than wild type control [36]. In this line, Das et al., 2015, demonstrated an 
increase in CD206+ DCs mobilization at the CHIKV infected astrocytes site [37].
Nevertheless, it is well documented that innate immunity following viral infec-
tion can recruit inflammatory cells to infected musculoskeletal tissues, with the 
potential to cause muscular and articular damages inducing the observed pain 
and discomfort in muscles, joints, and tendons [16]. This CHIKV dependent 
polyarthritis-like symptoms were reported by Amdekar et al., 2017, to be linked 
with host inflammatory response regulated by infiltrating macrophages (in joints), 
T cells, and viral persistence within the immune inaccessible infected sites [38]. 
Similarly, numerous studies have demonstrated the dichotomic CHIKV reservoir 
(during chronic infection phase) and modulatory macrophage functions (keeping 
Figure 3. 
Chikungunya virus genome structure and infectious cycle. (A) Chikungunya genome structure, (B) 
chikungunya (CHIK) internalizes within the target cell through receptor mediated endocytosis. Upon 
entry, CHIK undergo conformational changes leading to E1 peptide exposure as a result of endosomal 
microenvironment acidity, which favors virus–host cell membrane fusion and subsequent cytoplasmic release 
of nucleocapsid core and viral genome. Thereafter, two viral mRNA strands are translated to give to two 
non-structural proteins (nsPs), which are cleaved to generate nsP1–nsP4.The function of the latter are as 
followed: 1) nsP1 synthesis the negative viral strand RNA and cap it, 2) nsP2 exhibits RNA triphosphatase, 
helicase and proteinase functions contributing to host cell transcriptional machinery inhibition, 3) nsP3 forms 
part of the replicase unit and 4) nsP4 exert viral RNA polymerase function. The coordinated activity of these 
proteins is to produce the viral replication complex, enabling the synthesis of the full-length negative-strand 
RNA intermediate serving as the precursor to generate the subgenomic (26S) and genomic (49S) RNAs. 
Once synthesized, the 26S mRNA is translated into C–pE2–6 K–E1 polyprotein precursors, which are further 
processed by a serine protease to produce a capsid (C), pE2 and E1 glycoproteins. Then, pE2 and E1 assemble 
in the Golgi and translocate to the plasma membrane, where pE2 is cleaved into E2 (enabling receptor 
binding) and E3 (ensuring correct pE2 folding and its subsequent assembly with E1). Completion of this viral 
replication cycle is achieved through 1) assembly of the viral nucleocapsid with the viral RNA, 2) recruitment 
of membrane-associated envelope glycoproteins and 3) budding at the virus at the host cell membrane [24].
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local Th1/Th2 balance) in the affected tissues (muscles, joints, lymphoid tissues and 
liver) that they co-infiltrated with mononuclear inflammatory cells [39–41]. These 
aforementioned results corroborated Gardner et al., 2010 study, revealing the equally 
important role of macrophages in establishing arthritis symptoms and CHIKV clear-
ance [42]. Furthermore, Phuklia et al., 2013 and Schett, 2007 showed that CHIKV-
infected synoviocytes (Cells producing the synovial fluid component important for 
absorption from the joint cavity and for synovial/blood fluid exchange) were able 
to promote the migration and differentiation of both monocytes and macrophages 
into joints damaging osteoclast-like cells, capable of producing high levels of arthritis 
mediators (Interleukin-6 and Tumor Necrosis Factor-α) [43, 44]. In contrast, Haist 
et al., 2017, underlined the protective role of inflammatory Ly6Chi CCR2+ monocytes 
in controlling CHIKV infectious, as their depletion (using diphtheria toxin on CCR2-
DTR+ mice) was associated with severe disease symptoms and reduction in Ly6C and 
NK cells in bloodstream and muscles when compared to wild type mice [45].
6. Chikungunya and adaptive immunity
Humoral and cell-mediated immunity hold the center stage for protection 
against CHIKV infection through the combined action of T and B-lymphocytes, 
respectively [46]. Multiple human and animal studies have demonstrated the host 
immune system’s ability to induce the production of neutralizing anti-CHIKV 
antibodies, to rapidly clear CHIKV viral loads and establish long-term immunity 
[1, 10, 46]. This adaptive humoral immunity relies on immunoglobulin-M (IgM: 
representing ~30% of circulating antibodies) to primarily entrap the CHIKV 
antigen to secondary lymphoid tissues by bridging the innate and adaptive immu-
nity before the onset of the robust and specific life-long protecting IgG response [1, 
47]. During the chikungunya fever acute phase, neutralizing IgM are produced as 
early as 2–6 days post-infection and act to reduce viral loads (Figure 4) [48]. This 
neutralizing IgM capacity perdures up to 10 days following CHIKV infection before 
synergizing with specific IgG response [1]. Interestingly, Couderc and Lecuit et 
al.,2015 reported persistent anti-CHIKV IgM in chronic chikungunya fever patients 
related to repeated CHIKV antigen and RNA exposure [49]. Of late, Tanabe et al., 
2018 showed that IgM antibodies preferentially interact with cognate E1-E2 fusion 
glycoprotein epitopes found on CHIKV outer surface [23, 46] and that long term 
viral immune protection was achieved through specific IgG production, persist-
ing up to 19 years following the first infectious episode (1991 Thailand CHIKV 
outbreak) [50]. Among all IgG subtypes, IgG3 was found to be the most predomi-
nant, able to serve as a predictive marker of high-risk patients (when minimally 
produced) or as a prophylactic agent, able to passively transfer from mother to 
newborn via the placenta and limit viral metastases to distant muscles and joints 
[1]. This pentameric immunoglobulin structure armed them with the ability to 
easily mediate CHIKV aggregation, recognition and elimination by cytotoxic CD8+ 
T cells [46]. Unfortunately, CD4+ T-cells can be detrimental to CHIKV infected 
mice, as it was reported by Theo et al., 2017 that they can severely damage the joints 
of T-cell receptor-deficient mice when adoptively transferred [46, 51]. Mitigation of 
these undesired CD4+ T-cell effects could be performed using fingolimod (phos-
phorylated sphingosine 1-phosphate receptor 1 agonist: S1PR1) treatment, blocking 
S1PR1 mediated CD4+ T-cells dissemination to the joints of CHIKV infected mice 
[46, 51]. In a parallel study, Miner et al., 2017 demonstrated the synergy of immu-
nosuppressive cytotoxic T-lymphocyte-antigen-4 (CTLA-4) abatacept (blocking 
CD4 co-stimulatory activating signals) with anti-CHIKV (reducing viral load) 
in controlling arthritis and CHIKV infection, respectively [52]. This result was 
Chikungunya
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particularly relevant, as it may pave the way for novel antibody therapeutic strate-
gies, with the potential to clinically benefit CHIKV infected patients.
7. Chikungunya virus therapeutic treatment and future perspectives
Targeted antibody-based immunotherapy was developed to address the unmet 
CHIKV therapeutic clinical needs [1]. In this regard, immunotherapy using IgG has 
widely been developed and has demonstrated the potential to reach clinical frui-
tion by exerting its virucidal (Virus killing activity) and prophylactic activities on 
infected patients [1]. This IgG virucidal effect was confirmed by Scott et al., 2017 
showing its ability to induce complete recovery in encephalitis infected patients, 
using a therapeutic dose of 400 mg/kg for 5 days [2]. With this in mind, Fernandes 
et al., 2019 corroborated these latter results, by achieving a 10 day total recovery, 
following a combination therapy involving antibiotic and IgG treatment (400 mg/
kg for 5 days) on a severely infected 56 years old patient, presenting with atypical 
dermatological form associated with edema and hemorrhagic bullous skin lesions 
[53]. This IgG immunotherapeutic agent could either be used to immunized healthy 
or asymptomatic individuals in endemic areas (with the aim to reduce CHIKV 
propagation) or to treat high-risk patients such as pregnant women, newborns, 
immunocompromised individuals, elders or patients with preexisting arthritis [1]. 
For example, Couderc et al. 2009 demonstrated the therapeutic and prophylactic 
actions of IgGs (purified from convalescent CHIKV infected donor), protecting 
adult immunocompromised and immunocompetent mice neonates from CHIKV 
Figure 4. 
CHIKV infection and immune response: CHIKV infection begin with mosquito’s bites, allowing viral entry into 
serum and subsequent dissemination into peripheral organs (lymphoid, muscles and joints), leading to the onset 
of symptoms (acute phase) that can perdure beyond 8 days. During the acute phase (0–4 days), neutralizing 
IgMs are produced, and their increase inversely correlates with CHIKV viral loads. During the recovery phase 
or convalescence (beyond 7 days), IgGs are produced and act in concert with IgM to provide long-term immune 
protection.
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re-challenge and severe neurological symptoms associated with chronic CHIKV 
infection [54]. Based on these accumulative reports, a phase I/II clinical trial was 
initiated to evaluate the therapeutic and prophylactic efficacy of CHIKV IgG 
therapy to newborns of mothers with acute CHIKV infection, whose infectious 
rates reached 49% (Clinical trials: NCT02230163) [14]. However, the efficacy of 
CHIKV IgG immunotherapy can be compromised by immune evasion, arising from 
monoclonal Abs (mAbs) selective pressure or accumulated genetic mutations able 
to suppress antigen specificity, thus antigen–antibody interaction [1]. With the 
advent of recombinant antibody engineering technology, efforts to overcome these 
unwanted effects were developed and led to the generation of bispecific antibodies 
that can recognize two or more epitopes; a detailed discussion beyond the scope 
of this review has been provided by Nyakatura et al., 2017 [55]. Besides immune 
evasion, other factors like antibody-dependent enhancement (ADE), characterized 
by sub-neutralizing Abs concentration that is permissive for viral replication, has 
been identified as a major challenge for CHIKV management [1, 56]. In spite of the 
single serotype status of CHIKV, ADE cannot be overlooked with respect to CHIKV 
reemergence, as it has been observed in other viral diseases, including Dengue, 
Rabies virus, influenza and HIV [1]. Also, antibody-based therapy is generally 
associated with high production costs, which may restrain therapeutic usage due 
to affordability. To address these issues, nucleic acid vaccines made up of mRNA or 
Figure 5. 
mRNA vaccine mechanism of action. Conventional mRNA possesses disease specific gene of interest (GOI) 
encoding the antigen DNA sequence that is respectively capped at the 5′ end and polyadenylated (poly-a tail) 
at the 3′ untranslated region (UTR). Upon internalization within the host cell, viral mRNA is released from 
the endosome to the cytosol, where it is immediately translated by the ribosomes and post-translationally 
modified by the proteasome. In opposition to the conventional mRNA vaccination, the self-amplifying mRNA 
method mostly uses positive-sense single-stranded viral RNA encoding the disease specific antigen and viral 
nonstructural proteins (nsPs) driving intracellular RNA amplification and significant antigen expression. 
These two vaccination methods need a delivery system for host cell internalization, commonly performed 
through endocytosis, preceding cytosolic viral mRNA cargo releases from the endosome, driving translation and 
subsequent viral antigen protein processing for MHC presentation to ensue and activate host immunity [59].
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plasmid DNA (pDNA) were developed [57, 58]. These novel vaccines are commonly 
used to treat mRNA alphavirus and are mainly produced by genetically substituting 
viral encoding structural protein with target antigen encoding genes while preserv-
ing the RNA replication machinery [57]. Hence, when injected into patients, these 
vaccines (mRNA) mimic the virus by taking advantage of the host cell machinery to 
efficiently transcribe an antigen encoded RNA into an antigen encoded DNA, which 
is subsequently translated and post-translationally modified into a form (protein) 
that resemble the natural antigen that can successively stimulate and activate the 
innate and adaptive immunity (Figure 5) [57, 58]. Recently, Kose et al. (2019) 
demonstrated CHIKV and arthritis protecting properties of an infused nanoparticle 
encoding CHIKV antibody mRNA, which was as good as purified IgG mAbs in 
stimulating protective anti-CHIKV serum concentrations in macaques [60].
So far, there are no clinically approved RNA vaccines to treat human diseases. 
Yet, in response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, 
multiple clinical trials such as NCT04283461, have been initiated to test the safety 
of an mRNA vaccine (encoding SARS-CoV-2 spike protein), which successfully 
produced SARS-CoV-2 antibodies and had no clinically adverse effects [61, 62]. 
Currently, it has progressed into phase III clinical trial (NCT04470427) to evalu-
ate its efficacy against COVID-19. Likewise, other clinical trials are presently 
investigating the safety, tolerability and immunogenicity of zika virus envelop 
protein encoded mRNA vaccines (NCT04064905; NCT03014089) [61, 63]. Taken 
altogether, it becomes evident that the rapid advances made in recombinant DNA 
technology, will revolutionize the way we approach and promptly respond to 
endemic CHIKV/COVID-19 like diseases.
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